Dekavil is a Fusion Protein owned by Pfizer, and is involved in 4 clinical trials, of which 2 were completed, 1 is ongoing, and 1 is planned.

Dekavil is a human antibody F8 fused to IL-10. It binds to the alternatively spliced extra-domain A of fibronectin and results in the targeted delivery of the anti-inflammatory cytokine IL-10 to the arthritic lesions. IL-10 functions as an immunoregulatory molecule by inhibition of cytokine synthesis and down regulation of antigen presenting cell function. F8-IL10 may have therapeutic potential in the treatment of the disease by the targeted delivery of anti-inflammatory cytokine.

The revenue for Dekavil is expected to reach a total of $306m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dekavil NPV Report.

Dekavil was originated by Philogen and is currently owned by Pfizer.

Dekavil Overview

Dekavil (F8-IL10) is under development for the treatment of rheumatoid arthritis. The drug candidate is administered intravenously, intraarticularly and subcutaneously as powder for solution. The drug candidate is a new biological entity (NBE). The drug candidate is an immuno-cytokine consisting of a vascular targeting antibody fused to the anti-inflammatory cytokine interleukin-10 (IL10). 

It was under development for the treatment of ulcerative colitis and crohn's disease.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – Dekavil

Report Segments
  • Innovator
Drug Name
  • Dekavil
Administration Pathway
  • Intraarticular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Immunology
Key Companies
  • Sponsor Company: Pfizer
  • Originator: Philogen
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.